Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies

NCT04662788 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Hematological Malignancies

Interventions

DRUG: NK cells/Combined Monoclonal Antibodies

Sponsor

Zhejiang University